van der Garde, M.* et al. Single-cell MultiOmic analysis of CHIP bone marrow stem and progenitor cells provides evidence of early-stage malignant transformation. Oncol. Res. Treat. 45, 264-265 (2022)
Zeller, T.* et al. Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages. Oncol. Res. Treat. 45, 2, 162-162 (2022)
Haffner, I.* et al. Treatment of HER2 positive advanced gastric cancer: Deviations in HER2 results and its impact on survival. Oncol. Res. Treat. 43, 65-65 (2020)
Cheney, C.P. et al. The association between serum 25-Hydroxyvitamin D and cancer risk: Results from the prospective KORA F4 study. Oncol. Res. Treat. 41, 117-121 (2018)
Haffner, I.* et al. Determination of HER2 in Gastric Cancer (GC) is still challenging: high deviation rates between local and central pathologies and its impact on survival. Oncol. Res. Treat. 41, 240-240 (2018)
Pfirrmann, M.* et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for prognosis of probabilities of dying of chronicphase chronic myeloid leukaemia. Oncol. Res. Treat. 41, 140-141 (2018)
Eichner, R.* et al. Immunomodulatory drugs destabilize CD98hc and LAT1 to interfere with amino acid transport and tumor metabolism. Oncol. Res. Treat. 40, 82-82 (2017)
Gary, R.* et al. Adoptive transfer of CMV- and EBV-specific peptide-stimulated T cells after allogeneic stem cell transplantation: First results of a phase I/IIa clinical trial [AIT-MULTIVIR-01]. Oncol. Res. Treat. 40, 239-239 (2017)
Habringer, S.* et al. CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 40, 214-214 (2017)
Jacobs, L.A.* et al. A study of Myc-regulated metabolic changes in transformed B cells. Oncol. Res. Treat. 40, 218-218 (2017)
Krupka, C. et al. Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML. Oncol. Res. Treat. 40, 84-85 (2017)
Lichtenegger, F.S. et al. Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: Results of a phase I/II trial and ex vivo enhancement by checkpoint blockade. Oncol. Res. Treat. 40, 135-135 (2017)
Richter, A.S.* et al. CK2 inhibition reduces cell proliferation in acute B-lymphoblastic leukemia cells in vitro and in vivo. Oncol. Res. Treat. 40, 20-20 (2017)
Friemel, I.* et al. Intratumor heterogeneity in hepatocellular carcinoma: Impact on tumor classifications and targeted therapies. Oncol. Res. Treat. 39, 81 (2016)
Gross, E.* et al. Validation of a BRCAness test to select for targeted therapies in triple-negative breast cancer. Oncol. Res. Treat. 39, 54 (2016)
Habringer, S.* et al. CXCR4-directed peptide receptor radiotherapy with 177Lu-Pentixather effectively clears leukemia in patient-derived xenografts. Oncol. Res. Treat. 39, 214-214 (2016)
Haffner, I.* et al. Clinical validation of response and resistance factor candidates to targeted therapy in Gastric Cancer (GC). Oncol. Res. Treat. 39, 16-17 (2016)
Jacobs, L.A.* et al. A study of Myc-regulated metabolic changes in transformed B cells. Oncol. Res. Treat. 39, 218-218 (2016)
Krupka, C. et al. Influence of cytoreductive and immunmodulatory drugs on antibody-based approaches in AML. Oncol. Res. Treat. 39, 84-85 (2016)
Lichtenedger, F.S. et al. Induction of antigen-specific T-cell responses through dendritic cell vaccination in AML: results of a phase I/II trial and ex vivo enhancement by checkpoint blockade. Oncol. Res. Treat. 39, 135-135 (2016)
Neff, F.* et al. Targeting notch for myeloid reprogramming in pancreatic cancer. Oncol. Res. Treat. 39, 16 (2016)
Trajkovic-Arsic, M.* et al. Identification of metabolic changes in pancreatic ductal adenocarcinoma. Oncol. Res. Treat. 39, 76-77 (2016)
Willier, S.* et al. Role of Thyroid Receptor Interacting Protein 6 (TRIP6) in migration and invasion of Ewing' sarcoma cells. Oncol. Res. Treat. 39, 145 (2016)
Bücklein, V.L. et al. Intratumoral immune cell infiltration in patients with high-grade soft-tissue sarcoma is associated with tumor grading. Oncol. Res. Treat. 38, 246-247 (2015)
Bücklein, V.L. et al. Immunotherapeutic strategies for soft-tissue sarcoma: Preclinical results of Natural Killer cell augmentation by ex vivo expansion and use of an anti-GD2 antibody. Oncol. Res. Treat. 38, 149-150 (2015)
Freysoldt, B. et al. Cotargeting of PIM, PI3K and mTOR in mantle cell lymphoma. Oncol. Res. Treat. 38, 63 (2015)
Garz, A.-K.* et al. The combination of crenolanib and azacitidine effectively targets leukemia-initiating cells in FLT3-ITD+ AML to overcome protection by the bone marrow niche. Oncol. Res. Treat. 38, 214 (2015)
Habringer, S.* et al. Very early functional in-vivo imaging to predict response to B cell receptor pathway targeting in lymphoma. Oncol. Res. Treat. 38, 99 (2015)
Hatzl, S.* et al. Loss of the tumor- and metastasis suppressor RAF kinase inhibitor protein is caused by the overexpression of miRNA-23a. Oncol. Res. Treat. 38, 99 (2015)
Köhnke, T. ; Rechkemmer, S.* ; Bücklein, V.L. ; Hiddemann, W.* & Subklewe, M. Feasibility of semi-automated MRD analysis by flow cytometry in acute myeloid leukemia. Oncol. Res. Treat. 38, 46 (2015)
Krupka, C. et al. Combining immune checkpoint inhibition with the CD33 BiTE (R) antibody construct AMG 330 to enhance T cell mediated lysis of primary AML cells. Oncol. Res. Treat. 38, 38 (2015)
Lichtenegger, F.S. et al. Next-generation dendritic cell vaccination in postremission therapy of AML: Results of a clinical phase I trial. Oncol. Res. Treat. 38, 37 (2015)
Zoellner, A.-K.* et al. The B-cell receptor pathway is highly actived in canine DLBCL cell line CLBL-1. Oncol. Res. Treat. 38, 65 (2015)
Bruns, H.* et al. Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high grade B-cell lymphoma. Oncol. Res. Treat. 37, 70 (2014)
Harnicek, D. et al. Hyperthermia combined with trabectedin prolongs G2 cell cycle arrest and reduces cellular survival in human tumor cells. Oncol. Res. Treat. 37, 116 (2014)
Hellmuth, J. et al. Gastrointestinal Follicular Lymphoma (FL) differs from nodal FL by absence of EZH2 mutations. Oncol. Res. Treat. 37, 75 (2014)
Jansen, L.* et al. Socio-economic deprivation and cancer survival in Germany. Oncol. Res. Treat. 37, 34 (2014)
Kobold, S.* et al. Bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. Oncol. Res. Treat. 37, 239 (2014)
Lichtenegger, F.S. et al. T cell differentiation but not exhaustion in AML. Oncol. Res. Treat. 37, 225 (2014)
Lichtenegger, F.S. et al. Next-generation dendritic cell vaccination as postremission therapy for AML patients with a non-favorable risk profile. Oncol. Res. Treat. 37, 310 (2014)
Malkomes, P.* et al. Characterization of colon cancer stem cells at the single cell level for target identification in diagnosis and therapy. Oncol. Res. Treat. 37, 120 (2014)
Neumann, M.* et al. T-ALL is characterized by heterogeneous pattern of gene mutations and their variant allele frequencies. Oncol. Res. Treat. 37, 180 (2014)
Peter, N. et al. Interaction of anti-CD20 antibodies and inhibitors of the B-cell receptor pathway in diffuse large B-cell lymphoma. Oncol. Res. Treat. 37, 72 (2014)
Yabal, M.* et al. Aberrant TNF signalling in dendritic cells in the absence of XIAP contributes to X-linked lymphoproliferative disease (XLP-2) by exaggerated necroptosis. Oncol. Res. Treat. 37, 246 (2014)
Zhao, Y.* et al. CXCR4 over-expression is associated with Cisplatin resistance in esophageal carcinoma. Oncol. Res. Treat. 37, 99 (2014)
Zoellner, A.-K. et al. Efficacy of PI3K-inhibitors in Mantle Cell Lymphoma (MCL). Oncol. Res. Treat. 37, 72 (2014)